A retrospective study covering 4,205 patients published in the April issue of The Journal of Urology reported a statistically significant decrease in original penile prosthesis infection rates. This is the first published study showing the benefits of American Medical Systems’ (Nasdaq:AMMD) InhibiZone(TM)(1) antibiotic treatment when integrated into a penile prosthesis. This was the first drug-eluting implantable medical device marketed in the U.S.
